[ad_1]
TORONTO and CAMBRIDGE, Mbad., March 19, 2019 (GLOBE NEWSWIRE) – ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of proprietary therapeutics. Antibody targeting toxic oligomers implemented development of neurodegenerative diseases, will present data on new candidate antibodies exhibiting strict selectivity for the toxic forms of alpha-synuclein, considered a fundamental cause of Parkinson's disease. ProMIS Neurosciences Scientific Director, Dr. Neil Cashman, will discuss preclinical data during a March 31 presentation on the podium, and will also lead the March 30th roundtable on the mechanisms of Alzheimer's and Parkinson's disease.
In his March 31 presentation titled "Targeting Pathogen Aggregated Alpha-Synucleins: Improving Antibody Epitopes by Design," Dr. Cashman will present data showing how the new ProMIS drug discovery and development platform has created antibodies that:
- Selectively bind to the toxic forms of alpha-synuclein while sparing the healthy forms of alpha-synuclein that are essential for proper cell metabolism and communication
- Block neurotoxicity and the spread of toxic forms of alpha-synuclein in vitro
"The ability to bind toxic forms and only The toxic forms of misfolded proteins in the brain have been an extremely difficult challenge in both the development of Parkinson's and Alzheimer's drugs, "said Dr. Neil Cashman, a leading researcher. in the field of diseases related to protein misfolding. "This is due in large part to the fact that the toxic species of the affected proteins still share many similarities with the healthy forms of the protein, making them impossible to accurately target with traditional antibody development tools. Thanks to our unique discovery platform, we have been able to solve this problem successfully. Our data shows that we can produce antibodies that bind toxic species and only toxic alpha-synuclein species with exquisite precision while preserving healthy forms of the protein. "
Alpha-synuclein is an essential brain protein that can form misfolded toxic clusters (aggregates), leading to the progressive destruction of neurons in the brain. Two decades of research indicates that these toxic forms of alpha-synuclein are the cause of Parkinson's disease and represent a major therapeutic target for drug development.
At the conference, Dr. Neil Cashman will also co-moderate the panel entitled "Disease-Related Mechanisms of Alzheimer's Disease and Parkinson's Disease," which will highlight efforts to deepen understanding of the detailed mechanisms involved in these diseases.
AD / PD 2019, the 14th International Conference on Alzheimer's and Parkinson's Diseases and Associated Neurological Disorders, is taking place in Lisbon, Portugal, from March 26 to 31, 2019. For more information or to to register, please visit AD / PD 2019 conference site.
About ProMIS Neuroscience
ProMIS Neurosciences, Inc. is a development-stage biotechnology company dedicated to the discovery and development of antibody-based therapies that selectively target toxic oligomers involved in the development and progression of neurodegenerative diseases, particularly disease. Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). The company's proprietary target discovery platform is based on the use of two complementary discovery engines, thermodynamics and calculators – ProMIS and Collective Coordinates – to predict new targets, known as disease-specific epitopes, on the molecular surface. misfolded proteins. Using this unique precision approach, the Company is developing novel antibody-based therapies for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario with offices in Cambridge, Mbadachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN and on the OTCQB risk market under the symbol ARFXF.
Come visit us at www.promisneurosciences.com or follow us on Twitter and LinkedIn
For media inquiries, please contact:
Shanti Skiffington
[email protected]
Such. 617-921-0808
For investor relations, please contact:
Alpine Equity Advisors
Nicholas Rigopulos, President
[email protected]
Such. 617 901-0785
The TSX has not reviewed and accepts no responsibility for the adequacy or accuracy of this release. This press release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that could cause actual results, performances or achievements to differ materially from those implied in these statements. These statements should not be read as guarantees of performance or future results. All forward-looking statements are based on the Company's current beliefs, current badumptions and information, and other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to the risks and uncertainties, including the risks and uncertainties identified by the Corporation in its securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Source link
